Education only — not medical advice
Pharmacotherapy education
Class overviews only — no doses. Confirm candidacy and labels with your clinician.
Medication classes
GLP-1 receptor agonists
liraglutide, semaglutide
Adult obesity themes; WHO 2025 conditional for BMI ≥30 with lifestyle adjunct; equity/access caveats. Not a dosing cookbook.
Dual GIP/GLP-1 agonist
tirzepatide
Broad adult obesity / overweight+comorbidity themes; preferred in several 2025–2026 hierarchies (VA/DoD, ADA, EASO).
GI lipase inhibitor
orlistat
Older, widely listed option; always with diet counselling.
Combination AOMs (region-limited)
phentermine–topiramate; naltrexone–bupropion
Availability varies by country; confirm local label — never self-start.
Melanocortin-4 receptor agonist
setmelanotide
Rare genetic obesity only (NIDDK). Not a general weight-loss drug.
Sources: WHO GLP-1 2025, NIDDK meds, AACE 2025, EASO pharma framework — see Trust Library.
Candidate prep quiz
Answer for yourself, then generate questions for your doctor. This never says you “qualify.”
Contraindication awareness (education)
- Pregnancy / planning pregnancy — incretin therapies typically excluded; confirm with clinician + label.
- Personal/family history themes relevant to some incretin labels (e.g. MTC/MEN2) — screening is clinician territory.
- History of pancreatitis or severe GI disease — discuss before any AOM conversation.
- Active eating-disorder symptoms — escalate to specialist care; do not self-start weight drugs.
Discuss with your clinician
Off-ramp & maintenance planner
Weight regain after stopping incretin therapies is well documented in trials (e.g. STEP-1 extension). Use this checklist with your prescriber — do not self-taper.
- Ask: what maintenance plan do we use if we pause or stop?
- Ask: how will we monitor regain and muscle/protein intake?
- Ask: what behavioural support continues after the medicine?
- Do not self-taper or share pens — follow the prescriber and official leaflet.